MilliporeSigma and InnoCore Pharmaceuticals to Improve Patient Compliance with New Drug Delivery Technology
MilliporeSigma and InnoCore Pharmaceuticals have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys® biodegradable polymer platform.
- Platform for creating sustained release formulations for virtually any class of biological API
- Eliminates pharmaceutical development hurdles
- MilliporeSigma’s global footprint makes InnoCore’s proprietary SynBiosys® drug delivery technology platform more widely available
Burlington, Massachusetts, July 26, 2018 – MilliporeSigma and InnoCore Pharmaceuticals; Groningen, Netherlands, have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys® biodegradable polymer platform. The drug delivery platform can be used to develop sustained release solutions for biologicals in injectable formulations.
“Until now, formulating large biological active pharmaceutical ingredients such as proteins and large peptides into long-acting sustained release formulations has been difficult, if not impossible,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “This collaboration will bring long-acting release of protein therapeutics to market, allowing new and potentially life-changing treatments. It will also improve patient compliance by reducing dosing frequency and maintaining drugs at therapeutic levels longer.”
Sustained release solutions play an increasingly important role in drug formulation because they enhance patient adherence. The new proprietary technology developed by InnoCore Pharmaceuticals allows the development of injectable sustained release biological formulations with conserved bioactivity of these sensitive molecules. The SynBiosys® platform can be used for subcutaneous, intramuscular and site-specific injectable formulations in the form of microparticles and implants.
MilliporeSigma and InnoCore will support customers with formulation, process development and manufacturing services in using this technology to develop injectable sustained release drug products and overcome formulation challenges — especially for large peptides and proteins. This new, large biomolecule formulation and delivery capability complements MilliporeSigma’s existing portfolio of biodegradable polylactic acid and polylactic glycolic acid (PLA/PLGA) polymers for sustained release in liquid/parenteral formulations. The PLA/PLGA technology applies primarily to small molecules, small hormones and peptides.
Poor compliance in the treatment of chronic diseases is a significant problem. The cost of non-compliance in the U.S. alone is estimated at between $100 billion and $290 billion per year, according to a January 2018 article published by the U.S. National Library of Medicine National Institutes of Health.
Said Jan Hendriks, CEO, InnoCore Pharmaceuticals, “We are very excited that we have been able to set up this important collaboration with MilliporeSigma, a company that is widely recognized in providing drug formulation solutions for the global life sciences industry.”
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany Highlights Commitment to Improving Cancer Outcomes ...
Merck KGaA, Darmstadt, Germany, announced 43 abstracts covering modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US.